Patents Assigned to Synthorx, Inc.
-
Publication number: 20240082359Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: June 1, 2023Publication date: March 14, 2024Applicant: Synthorx, Inc.Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
-
Patent number: 11919934Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.Type: GrantFiled: August 25, 2020Date of Patent: March 5, 2024Assignee: SYNTHORX, INC.Inventors: Carolina E. Caffaro, Jerod Ptacin, Marcos Milla
-
Publication number: 20240043823Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.Type: ApplicationFiled: October 4, 2023Publication date: February 8, 2024Applicants: Synthorx, Inc., The Scripps Research InstituteInventors: Jerod PTACIN, Carolina CAFFARO, Hans AERNI, Yorke ZHANG, Emil C. FISCHER, Aaron W. FELDMAN, Vivian T. DIEN, Floyd E. ROMESBERG
-
Publication number: 20230416327Abstract: Disclosed herein are methods and uses relating to administering IL-2 conjugates or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-2 conjugates.Type: ApplicationFiled: April 6, 2023Publication date: December 28, 2023Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
-
Patent number: 11834689Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.Type: GrantFiled: March 9, 2021Date of Patent: December 5, 2023Assignees: THE SCRIPPS RESEARCH INSTITUTE, SYNTHORX, INC.Inventors: Jerod Ptacin, Carolina Caffaro, Hans Aerni, Yorke Zhang, Emil C. Fischer, Aaron W. Feldman, Vivian T. Dien, Floyd E. Romesberg
-
Publication number: 20230302089Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: March 6, 2023Publication date: September 28, 2023Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Marcos MILLA, Jerod PTACIN
-
Publication number: 20230277627Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with pembrolizumab.Type: ApplicationFiled: April 6, 2023Publication date: September 7, 2023Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
-
Patent number: 11701407Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: GrantFiled: February 27, 2020Date of Patent: July 18, 2023Assignee: SYNTHORX, INC.Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
-
Patent number: 11622993Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: GrantFiled: August 3, 2018Date of Patent: April 11, 2023Assignee: SYNTHORX, INC.Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
-
Publication number: 20220324792Abstract: Disclosed herein are methods of preparing N6-((2-azidoethoxy)carbonyl)lysine, N6-((2-azidoethoxy)carbonyl)-L-lysine, and N6-((2-azidoethoxy)carbonyl)-D-lysine. Also disclosed herein are the compounds tert-butyl N2-(tert-butoxycarbonyl)-N6-((2-chloroethoxy)carbonyl)-L-lysinate and tert-butyl N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate, and uses thereof.Type: ApplicationFiled: June 21, 2022Publication date: October 13, 2022Applicant: Synthorx, Inc.Inventors: Hans AERNI, Randall SCHEUERMAN, Nikolai F. SEPETOV, Alexander V. SHIROKOV
-
Publication number: 20220273767Abstract: Disclosed herein are interleukin 10 (IL-10) conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates.Type: ApplicationFiled: May 3, 2022Publication date: September 1, 2022Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
-
Publication number: 20220016249Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: June 17, 2021Publication date: January 20, 2022Applicant: Synthorx, Inc.Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
-
Publication number: 20220016252Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.Type: ApplicationFiled: June 24, 2021Publication date: January 20, 2022Applicant: Synthorx, Inc.Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
-
Publication number: 20210338829Abstract: Disclosed herein are interleukin 10 conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates.Type: ApplicationFiled: May 6, 2021Publication date: November 4, 2021Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
-
Patent number: 11077195Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: GrantFiled: July 1, 2020Date of Patent: August 3, 2021Assignee: SYNTHORX, INC.Inventors: Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
-
Publication number: 20210070827Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: September 9, 2020Publication date: March 11, 2021Applicant: Synthorx, Inc.Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
-
Publication number: 20210054040Abstract: Disclosed herein are interleukin (IL)-15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates. In some embodiments, at least one amino acid residue in the IL-15 conjugate is replaced by the structure of Formula (I) described herein.Type: ApplicationFiled: August 21, 2020Publication date: February 25, 2021Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
-
Publication number: 20210046160Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) in combination with other agents or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: August 14, 2020Publication date: February 18, 2021Applicant: Synthorx, Inc.Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA
-
Publication number: 20200399338Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.Type: ApplicationFiled: August 25, 2020Publication date: December 24, 2020Applicant: Synthorx, Inc.Inventors: Carolina E. CAFFARO, Jerod PTACIN, Marcos MILLA
-
Publication number: 20200330601Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).Type: ApplicationFiled: July 1, 2020Publication date: October 22, 2020Applicant: Synthorx, Inc.Inventors: Jerod PTACIN, Carolina E. CAFFARO, Marcos MILLA